Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the superiority of the effectiveness of
Henagliflozin 10 milligram (mg) daily versus blank control in participants with type II
diabetes (T2DM) and symptomatic heart failure (HF) in improving the overall Kansas City
Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS).
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University